Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 556 of 5804
-
New drug targets Hard-to-Treat cancers with PI3K mutation
Disease control OngoingOKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other anti-cancer drugs. Phase 1a (Part A) wil…
Phase: PHASE1 • Sponsor: OnKure, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Virtual reality takes aim at gun violence in new trial
Disease control Recruiting nowThe overall aim of the proposed project is to develop and evaluate the effectiveness of Brief Violence Intervention-Virtual Reality (BVI-VR) for reducing firearm-related violence, re-injury, and mortality among victims of violence. Outcome measures of firearm-related violence wil…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for advanced anal cancer: chemo before radiation may boost survival
Disease control Recruiting nowSquamous cell carcinoma of the anus is still a rare disease but its incidence increases mostly due to its association with human papillomavirus (HPV). When localized, the standard treatment combines radiotherapy and chemotherapy with 5FU and mitomycin-C. Chemoradiotherapy (CRT) a…
Phase: PHASE3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 26, 2026 12:50 UTC
-
New pill could stop swelling attacks in hereditary angioedema
Disease control CompletedThis is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryn…
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a light bulb ease Parkinson's? new trial seeks answers
Symptom relief OngoingThis is a pivotal study to determine whether light therapy can improve non-motor and motor function in Parkinson's disease, on top of current best medical treatment.
Phase: NA • Sponsor: PhotoPharmics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take on advanced kidney cancer in new trial
Disease control OngoingThis is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Phase: PHASE1, PHASE2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a kidney drug for type 2 diabetes also help type 1 patients?
Disease control CompletedResearchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes. In people with type 1 diabetes, the body does not make enough of a hormone called insulin, resulting …
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2…
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a blood transfusion save kids with severe malaria?
Disease control Recruiting nowOpen-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
Phase: NA • Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo aims to boost immune attack on HPV throat cancer before surgery
Disease control OngoingThe majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. However, targeting tumors with stereotactic radiation in combination with immunotherapy while sparing draining lymphatics enhances anticancer immunity, r…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a smartphone app prevent suicide? new trial tests jaspr in the ER
Symptom relief Recruiting nowThis Study will comprehensively evaluate a multi-component suicide prevention technology (Jaspr Health) that facilitates delivery of suicided-related evidence-based practices (EBPs) while replacing wasted waiting time with productive time in the Emergency Departments (EDs). The E…
Phase: NA • Sponsor: University of Massachusetts, Worcester • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Immunotherapy combo shows promise in shrinking lung tumors before surgery
Disease control OngoingThe purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidatio…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for rare muscle disease: experimental drug enters human trials
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ARO-DUX4 in participants with facioscapulohumeral muscular dystrophy Type 1 (FSHD1). In Part 1 of the study, participants will receive one dose of ARO-DUX4 or pla…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Foam plug could open door to lung valve therapy for thousands
Disease control Recruiting nowThis is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV…
Phase: NA • Sponsor: Pulmonx Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo shows promise for hard-to-treat HER2 cancers
Disease control OngoingThis is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing soli…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for duchenne: experimental drug targets genetic glitch
Disease control Recruiting nowThis is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered o…
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New diabetes drug retatrutide takes on semaglutide in major trial
Disease control OngoingThe purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New lung cancer drug shows promise in phase 3 trial
Disease control OngoingThis clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based ch…
Phase: PHASE3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New triple inhaler aims to cut heart and lung emergencies in COPD
Disease control Recruiting nowThis study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New Four-Drug cocktail aims to crush resistant myeloma
Disease control Recruiting nowThe investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard…
Phase: PHASE2 • Sponsor: Benjamin T Diamond, MD • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC